Differentiated Thyroid Cancer Recurrence and Mortality Prognostic Factors: A Retrospective Cohort Study on 350 Adult Patients

Document Type : Original

Authors

1 Hamadan University of Medical Sciences, Hamadan, Iran.

2 Department of Epidemiology and Biostatistics, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran.

3 Department of Endocrinology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.

10.22038/ijorl.2026.93088.4094

Abstract

Introduction:
Differentiated thyroid cancer (DTC) accounts for the most common types of thyroid cancer. The aim of the present study was to investigate the factors associated with recurrence and mortality after thyroidectomy in patients with diagnose of DTC in Hamadan, Iran.
Materials and Methods:
In this retrospective cohort study, 350 patients over 18 years old who underwent total thyroidectomy and ablation with radioactive iodine (RAI)  and had DTC based on pathology and followed up for ten years were studied. The univariate and multivariate logistic regression was used for determining the risk factors of recurrence and mortality of DTC at a significance level of 0.05. SPSS software (Version 26) was applied to analyze the data.
Results:
In the present study, 16.6% of the participants were male and 83.4% were female with a mean age of 40.7 ±14.7 years. Recurrence and mortality rates were obtained to be 26.9% and 4.9 %, respectively.  Overall, the risk of recurrence and death was significantly higher in older age, men, smokers, tumors larger than 4 cm and regional lymph node (p<0.05). For each additional year of life, the risk of recurrence and death increased by 4% and 9%, respectively (P =0.001 and p<0.001). Recurrence in men were 5.111 times more likely than women (p<0.001). A 6.002-fold increase in the risk of death was associated with smoking (P=0.008).
Conclusion:
Due to the high prevalence of DTC and on the other hand the good prognosis of this type of cancer, timely diagnosis and identification of risk factors of   recurrence and death are very important.

Keywords

Main Subjects


  1. Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021 Aug 15;127(16):3029-3030. doi: 10.1002/cncr.33587.
  2. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et. Al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834
  3. Fagin JA, Wells SA Jr. Biologic and Clinical Perspectives on Thyroid Cancer. N Engl J Med. 2016 Sep 15;375(11):1054-67. doi: 10. 1056 /NEJMra1501993
  4. Schmidbauer B, Menhart K, Hellwig D, Grosse J. Differentiated Thyroid Cancer-Treatment: State of the Art. Int J Mol Sci. 2017 Jun 17;18(6):1292. doi: 10.3390/ijms18061292. 
  5. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006 May 10;295(18):2164-7. doi: 10.1001/jama.295.18.2164
  6. Li M, Brito JP, Vaccarella S. Long-Term Declines of Thyroid Cancer Mortality: An International Age-Period-Cohort Analysis. Thyroid. 2020 Jun;30(6):838-846. doi: 10.1089/thy.2019.0684.
  7. Matsuzu K, Sugino K, Masudo K, Nagahama M, Kitagawa W, Shibuya H, et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg. 2014 Jan;38(1):68-79. doi: 10.1007/s00268-013-2224-1.
  8. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994 Nov;97(5):418-28. doi: 10.1016/0002-9343 (94) 90321-2. 
  9. Satapathy S, Majeed AK, Ballal S, Bal C. Differentiated Thyroid Cancers in Young Adults Versus Children: Clinical Characteristics and 10-year Follow-up Outcomes. J Clin Endocrinol Metab. 2023 Nov 17;108(12):e1670-e1677. doi: 10.1210/clinem/dgad343.
  10. Grønlund MP, Jensen JS, Hahn CH, Grønhøj C, Buchwald CV. Risk Factors for Recurrence of Follicular Thyroid Cancer: A Systematic Review. Thyroid. 2021 Oct;31(10):1523-1530. doi: 10.1089/thy.2020.0921.
  11. Ywata de Carvalho A, Kohler HF, Gomes CC, Vartanian JG, Kowalski LP. Predictive factors for recurrence of papillary thyroid carcinoma: analysis of 4,085 patients. Acta Otorhinolaryngol Ital. 2021 Jun;41(3):236-242. doi: 10.14639/0392-100X-N1412.
  12. Hay ID, Johnson TR, Kaggal S, Reinalda MS, Iniguez-Ariza NM, Grant CS, et al. Papillary Thyroid Carcinoma (PTC) in Children and Adults: Comparison of Initial Presentation and Long-Term Postoperative Outcome in 4432 Patients Consecutively Treated at the Mayo Clinic During Eight Decades (1936-2015). World J Surg. 2018 Feb;42(2):329-342. doi: 10.1007/s00268-017-4279-x.
  13. Tufano RP, Clayman G, Heller KS, Inabnet WB, Kebebew E, Shaha A, etal; American Thyroid Association Surgical Affairs Committee Writing Task Force. Management of recurrent/persistent nodal disease in patients with differentiated thyroid cancer: a critical review of the risks and benefits of surgical intervention versus active surveillance. Thyroid. 2015 Jan;25(1):15-27. doi: 10. 1089/ thy. 2014.0098. 
  14. Scheffel RS, Zanella AB, Dora JM, Maia AL. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma. Thyroid. 2016 Nov;26(11):1623-1629. doi: 10.1089 /thy.2016. 0038.
  15. Van Den Heede K, Tolley NS, Di Marco AN, Palazzo FF. Differentiated Thyroid Cancer: A Health Economic Review. Cancers (Basel). 2021 May 7;13(9):2253. doi: 10.3390/cancers13092253.
  16. Amdur RJ, Mazzaferri EL. Factors that Predict Cancer Recurrence and Death from Differentiated Thyroid Cancer. InEssentials of Thyroid Cancer Management 2005 (pp. 131-140). Boston, MA: Springer US
  17. Megwalu UC, Saini AT. Racial disparities in papillary thyroid microcarcinoma survival. J Laryngol Otol. 2017 Jan;131(1):83-87. doi: 10.1017/S0022215116009737.
  18. Shah SA, Adam MA, Thomas SM, Scheri RP, Stang MT, Sosa JA, etal. Racial Disparities in Differentiated Thyroid Cancer: Have We Bridged the Gap? Thyroid. 2017 Jun;27(6):762-772. doi: 10.1089/thy.2016.0626.
  19. Keegan TH, Grogan RH, Parsons HM, Tao L, White MG, Onel K, etal. Sociodemographic disparities in differentiated thyroid cancer survival among adolescents and young adults in California. Thyroid. 2015 Jun;25(6):635-48. doi: 10.1089/thy.2015.0021. 
  20. Thewjitcharoen Y, Chatchomchuan W, Karndumri K, Porramatikul S, Krittiyawong S, Wanothayaroj E, etal. Impacts of the American Joint Committee on Cancer (AJCC) 8thedition tumor, node, metastasis (TNM) staging system on outcomes of differentiated thyroid cancer in Thai patients. Heliyon. 2021 Mar 30;7(3):e06624. doi: 10.1016/j.heliyon.2021.e06624.
  21. Ringel MD, Sosa JA, Baloch Z, Bischoff L, Bloom G, Brent GA, Brock PL, Chou R, Flavell RR, Goldner W, Grubbs EG, Haymart M, Larson SM, Leung AM, Osborne JR, Ridge JA, Robinson B, Steward DL, Tufano RP, Wirth LJ. 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer. Thyroid. 2025 Aug;35(8):841-985. doi: 10.1177/10507256251363120.
  22. Pałyga I, Rumian M, Kosel A, Albrzykowski M, Krawczyk P, Kalwat A, etal. The Frequency of Differentiated Thyroid Cancer Recurrence in 2302 Patients With Excellent Response to Primary Therapy. J Clin Endocrinol Metab. 2024 Jan 18;109(2):e569-e578. doi: 10.1210/ clinem/ dgad 571. 
  23. Wang H, Zhang C, Li Q, Tian T, Huang R, Qiu J, etal. Development and validation of prediction models for papillary thyroid cancer structural recurrence using machine learning approaches. BMC Cancer. 2024 Apr 8;24(1):427. doi: 10.1186/s12885-024-12146-4. 
  24. Hakim Tawil JA, Rojas MF, Santivañez JJ, León L, González Devia D. Prognostic factors for recurrence in patients with papillary thyroid carcinoma. Ear Nose Throat J. 2023 Feb 21: 1455613231158792. doi: 10.1177/014556132311 58792.
  25. Wan Z, Wang B, Yao J, Li Q, Miao X, Jian Y, etal. Predictive factors and clinicopathological characteristics of outcome in poorly differentiated thyroid carcinoma: a single-institution study. Front Oncol. 2023 Jul 7;13:1102936. doi: 10.3389/fonc.2023.1102936. 
  26. Ito Y, Kudo T, Kihara M, Takamura Y, Kobayashi K, Miya A, etal. Prognosis of low-risk papillary thyroid carcinoma patients: its relationship with the size of primary tumors. Endocr J. 2012;59(2):119-25. doi: 10.1507/endocrj.ej11-0288.
  27. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging. Ann Surg Oncol. 2007 Feb;14(2):730-8. doi: 10.1245/s10434-006-9207-5.
  28. Weber M, Binse I, Oebbecke K, Brandenburg T, Herrmann K, Theurer S, etal. Analysis of risk factors and prognosis in differentiated thyroid cancer with focus on minimal extrathyroidal extension. BMC Endocr Disord. 2021 Aug 10;21(1):161. doi: 10.1186/s12902-021-00826-2.
  29. Zahedi A, Bondaz L, Rajaraman M, Leslie WD, Jefford C, Young JE, etal. Risk for Thyroid Cancer Recurrence Is Higher in Men Than in Women Independent of Disease Stage at Presentation. Thyroid. 2020 Jun;30(6):871-877. doi: 10.1089/thy.2018.0775. 

 

  1. Kim JW, Roh JL, Gong G, Cho KJ, Choi SH, Nam SY, etal. Treatment Outcomes and Risk Factors for Recurrence After Definitive Surgery of Locally Invasive Well-Differentiated Papillary Thyroid Carcinoma. Thyroid. 2016 Feb;26(2):262-70. doi: 10.1089/thy.2015.0433. 
  2. Medas F, Canu GL, Boi F, Lai ML, Erdas E, Calò PG. Predictive Factors of Recurrence in Patients with Differentiated Thyroid Carcinoma: A Retrospective Analysis on 579 Patients. Cancers (Basel). 2019 Aug 22;11(9):1230. doi: 10.3390/cancers11091230. 
  3. Jeon MJ, Kim WG, Kim TH, Kim HK, Kim BH, Yi HS, etal; Korean Thyroid Cancer Study Group. Disease-Specific Mortality of Differentiated Thyroid Cancer Patients in Korea: A Multicenter Cohort Study. Endocrinol Metab (Seoul). 2017 Dec; 32(4):434-441. doi: 10.3803/ EnM. 2017. 32.4. 434.
  4. Adam MA, Thomas S, Hyslop T, Scheri RP, Roman SA, Sosa JA. Exploring the Relationship Between Patient Age and Cancer-Specific Survival in Papillary Thyroid Cancer: Rethinking Current Staging Systems. J Clin Oncol. 2016 Dec 20;34(36):4415-4420. doi: 10.1200/ JCO. 2016. 68. 9372.
  5. Pathak KA, Lambert P, Nason RW, Klonisch T. Comparing a thyroid prognostic nomogram to the existing staging systems for prediction risk of death from thyroid cancers. Eur J Surg Oncol. 2016 Oct;42(10):1491-6. doi: 10.1016/j.ejso.2016.05.016.
  6. Nilubol N, Kebebew E. Should small papillary thyroid cancer be observed? A population-based study. Cancer. 2015 Apr 1;121(7):1017-24. doi: 10.1002/cncr.29123. 
  7. Khazaei S, Abdollahi Yeganeh S, Salim Bahrami SAR, Borzouei S. Evaluation of Risk Factors Associated with Recurrence and Death in Patients with Thyroid Cancer From 2008 to 2023 in the West of Iran. J Res Health Sci. 2024 Sep 30;24(4):e00632. doi: 10.34172/jrhs.2024.167.